RenovoRx (RNXT.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec22

RenovoRx Inc. CEO Shaun Bagai Acquires Ordinary Shares of the Company

12:01

Dec19

RenovoRx Inc. CEO Shaun Bagai Acquires Company Common Stock

12:01

Dec11

RenovoRx Inc. to Present Pancreatic Cancer Treatment Clinical Trial Results at 2026 ASCO GI

13:30

Dec8

RenovoRx Inc. CMO and Director Ramtin Agah Purchases Company Shares

12:01

Nov15

Maxim Group Maintains Buy Rating on RenovoRx with a Price Target of $4.00

16:27

Nov14

RenovoRx released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 266 K (forecast USD 304 K), actual EPS USD -0.0799 (forecast USD -0.08)

00:00

Schedules & Filings

Schedules

Filings

Nov13

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 266 K, Net Income -2.912 M, EPS -0.0794

Aug14

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 422 K, Net Income -2.895 M, EPS -0.0791

May15

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 197 K, Net Income -2.42 M, EPS -0.077

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change